Delcath Systems (DCTH) AI Stock Analysis

• Market Cap: $338.31M
• Dividend Yield: N/A
• Average Volume (3M): 1.11M
• Price to Earnings (P/E): 1114.0
• Beta (1Y): 1.75
• Revenue Growth: 251.54%
• EPS Growth: N/A
• Country: US
• Employees: 96
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.02
• Shares Outstanding: 35,313,717
• 10 Day Avg. Volume: 849,364
• 30 Day Avg. Volume: 1,109,677
• PEG Ratio: 0.19
• Price to Book (P/B): 4.99
• Price to Sales (P/S): 9.23
• P/FCF Ratio: -17.84
• Enterprise Value/Market Cap: 1.01
• Enterprise Value/Revenue: 4.30
• Enterprise Value/Gross Profit: 4.99
• Enterprise Value/Ebitda: 24.01
• 1Y Price Target: $24.00
• Price Target Upside: 150.52% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): 0.04
• Revenue Forecast (FY): $85.76M

• Rating: 58 Neutral
• Price Target: $9.50 ▼(-0.84% Downside)

Delcath Systems' overall score reflects strong financial performance and promising earnings call highlights, tempered by weak technical indicators and high valuation concerns. The company's financial improvements and strategic advancements are offset by bearish market trends and valuation risks.

Positive Factors

Revenue Growth

The significant increase in revenue from HEPZATO indicates strong market demand and successful product adoption, supporting long-term growth.

Clinical Trial Success

Positive CHOPIN trial results enhance Delcath's competitive position in oncology, potentially leading to expanded market opportunities and partnerships.

Balance Sheet Health

A strong balance sheet with minimal debt enhances financial stability, providing Delcath with flexibility to invest in growth opportunities.

Negative Factors

Increased Operating Expenses

Rising R&D and SG&A expenses may pressure margins and profitability, potentially impacting financial performance if revenue growth doesn't offset costs.

Revenue Per Kit Decline

A decline in revenue per kit due to pricing pressures could affect overall profitability, necessitating strategic adjustments to maintain margins.

Decreased Net Income

A decrease in net income suggests challenges in maintaining profitability, which could impact future investments and shareholder returns.

Delcath Systems Business Overview & Revenue Model

Company Description

Delcath Systems, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of cancer. The company specializes in a proprietary drug delivery system, known as the Delcath Hepatic Perfusion System, which is designed to deliver high doses of chemotherapy directly to the liver while minimizing systemic exposure. Delcath operates primarily in the oncology sector, targeting patients with liver cancers, including metastatic melanoma and other liver tumors.

How the Company Makes Money

Delcath Systems generates revenue primarily through the sale of its proprietary medical devices and associated consumables, which are essential for its Hepatic Perfusion System. The company also pursues partnerships with healthcare institutions and pharmaceutical companies to expand the reach of its technology and enhance its product offerings. In addition to device sales, Delcath may generate revenue through clinical trial collaborations and potential licensing agreements for its technology. As the company seeks to gain regulatory approvals and expand its market presence, successful commercialization of its products and therapies will be crucial to its financial performance.

Delcath Systems Financial Statement Overview

Summary

Delcath Systems shows significant financial improvement with strong gross profit margins and positive revenue growth. The balance sheet is solid with minimal leverage, and cash flow generation is robust. However, historical volatility in revenue and profitability metrics suggests potential risks.

Income Statement

Delcath Systems shows a strong gross profit margin of 87.92% in the TTM, indicating efficient cost management. The net profit margin has improved significantly to 3.25% from negative margins in previous years, reflecting a turnaround in profitability. Revenue growth is positive at 13.33% in the TTM, although it has fluctuated in past years. The EBIT and EBITDA margins have also turned positive, suggesting operational improvements.

Balance Sheet

The company has a very low debt-to-equity ratio of 0.009, indicating minimal leverage and financial risk. Return on equity has improved to 3.40% in the TTM, showing better utilization of equity. The equity ratio stands at 92.37%, reflecting a strong equity base relative to total assets, enhancing financial stability.

Cash Flow

Free cash flow growth is robust at 211.25% in the TTM, indicating strong cash generation capabilities. The operating cash flow to net income ratio is 0.46, suggesting moderate cash conversion efficiency. The free cash flow to net income ratio is 0.80, showing that a significant portion of earnings is being converted into free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	79.60M	37.20M	2.06M	2.72M	3.56M	1.65M
Gross Profit	68.69M	31.02M	1.43M	2.03M	2.88M	1.01M
EBITDA	14.27M	-12.18M	-37.78M	-33.69M	-24.32M	-23.81M
Net Income	1.20M	-26.39M	-47.68M	-36.51M	-25.65M	-24.16M
Balance Sheet
Total Assets	124.30M	76.59M	38.61M	17.86M	33.12M	34.63M
Cash, Cash Equivalents and Short-Term Investments	88.91M	53.23M	32.45M	7.67M	22.80M	28.57M
Total Debt	965.00K	1.04M	10.19M	15.87M	16.25M	2.94M
Total Liabilities	9.45M	7.84M	22.84M	23.72M	21.17M	12.56M
Stockholders Equity	114.85M	68.75M	15.78M	-5.86M	11.95M	22.08M
Cash Flow
Free Cash Flow	12.04M	-19.24M	-31.31M	-25.16M	-22.75M	-23.65M
Operating Cash Flow	13.26M	-18.68M	-31.25M	-24.95M	-22.60M	-22.87M
Investing Cash Flow	-41.26M	-981.00K	-19.71M	-209.00K	-143.00K	-782.00K
Financing Cash Flow	61.38M	39.41M	51.78M	10.14M	20.82M	42.35M

Delcath Systems Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 9.58
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DCTH, the sentiment is Negative. The current price of 9.58 is above the 20-day moving average (MA) of 8.90, below the 50-day MA of 10.01, and below the 200-day MA of 12.12, indicating a neutral trend. The MACD of -0.14 indicates Negative momentum. The RSI at 48.93 is Neutral, neither overbought nor oversold. The STOCH value of 77.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DCTH.

Delcath Systems Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLPT	60 Neutral	$390.54M	―	-103.13%	―	12.83%	-19.53%
DCTH	58 Neutral	$338.31M	1,113.95	1.94%	―	251.54%	―
NNOX	54 Neutral	$255.37M	―	-34.75%	―	15.19%	-3.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SENS	45 Neutral	$238.61M	―	-129.29%	―	31.94%	36.59%
SRDX	43 Neutral	$614.51M	―	-15.36%	―	-0.02%	-1196.44%
TMCI	42 Neutral	$172.04M	―	-51.63%	―	7.90%	19.92%

Delcath Systems Corporate Events

Delcath Systems’ Earnings Call: Mixed Sentiments and Future Plans

The recent earnings call of Delcath Systems, Inc. painted a mixed picture, showcasing significant strides in clinical trials and revenue growth, yet also pointing out challenges like reduced revenue per kit and rising operating expenses that are affecting profitability.

Delcath Systems Reports Strong Q3 2025 Growth

Delcath Systems, Inc. is an interventional oncology company specializing in the treatment of primary and metastatic liver cancers through its proprietary products, HEPZATO KIT and CHEMOSAT, which deliver high-dose chemotherapy to the liver while minimizing systemic exposure.

Delcath Systems’ Promising Study on Liver-Directed Chemotherapy for Colorectal Cancer

Delcath Systems, Inc. is conducting a clinical study titled ‘An Open-label, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Induction Treatment With Melphalan/HDS Followed by Consolidation Treatment With Trifluridine-Tipiracil Plus Bevacizumab Versus Trifluridine-Tipiracil Plus Bevacizumab Alone in Patients With Refractory Metastatic Colorectal Cancer With Liver Dominant Disease.’ The study aims to assess the safety and effectiveness of a liver-directed high-dose chemotherapy treatment followed by standard cancer therapy compared to standard therapy alone in patients with metastatic colorectal cancer that has spread to the liver.

Delcath Systems’ New Study on Liver-Directed Chemotherapy for Metastatic Breast Cancer

Delcath Systems, Inc. has announced a new clinical study titled An Open-label, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Induction Treatment With Melphalan/HDS Followed by Consolidation Treatment With Eribulin or Vinorelbine or Capecitabine Versus Eribulin or Vinorelbine or Capecitabine Alone in Patients With Metastatic Breast Cancer With Liver Dominant Disease. The study aims to assess the safety and efficacy of a liver-directed therapy using high-dose chemotherapy for patients with metastatic breast cancer that has spread to the liver. This research is significant as it explores potential advancements in treatment options for this challenging condition.

Delcath Systems Reports Positive CHOPIN Trial Results

On October 18, 2025, Delcath Systems announced the results of the CHOPIN Trial, which showed that the combination of their CHEMOSAT Hepatic Delivery System with immune checkpoint inhibitors significantly improved progression-free survival in patients with metastatic uveal melanoma compared to PHP alone. Additionally, Delcath reported preliminary third-quarter financial results, revealing a total revenue of approximately $20.5 million, a net income of $0.8 million, and positive cash flow, indicating a strong financial position with no debt as of September 30, 2025.

The most recent analyst rating on (DCTH) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on Delcath Systems stock, see the DCTH Stock Forecast page.

Delcath Systems Updates Bylaws for Governance Efficiency

On August 12, 2025, Delcath Systems, Inc. amended and restated its Bylaws to clarify procedural requirements for stockholder nominations and proposals, update officer election provisions, and describe indemnification rights. These changes aim to modernize and streamline the company’s governance framework, potentially impacting its operational efficiency and stakeholder engagement.

The most recent analyst rating on (DCTH) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Delcath Systems stock, see the DCTH Stock Forecast page.